Pfizer opens $200m biologics clinical manufacturing facility in Andover, MA

US pharma giant Pfizer has opened Andover Clinical Manufacturing Facility (ACMF), a new 175,000sft biologics clinical manufacturing facility built with an investment of over $200 million in Andover, Massachusetts.

The biologics clinical manufacturing facility will be used for the development and production of complex biologics and vaccines and is expected to expand Pfizer’s BioTherapeutics Pharmaceutical Sciences’ capacity to manufacture clinical supplies.

The Andover Clinical Manufacturing Facility broke ground in June 2016 and had involved 200 jobs for its construction.

Charlie Baker – Massachusetts Governor said: “Massachusetts is a global hub for innovation and research, and our Administration is proud to have supported the expansion of one of the world’s premier biopharmaceutical companies right here in the Commonwealth.

“Pfizer’s expansion in Andover, combined with current operations in Boston and Cambridge, is a testament to the strength of this important sector of the Commonwealth’s economy, and Pfizer’s commitment to Massachusetts.”

Pfizer inaugurates $200m biologics clinical manufacturing facility in Andover, MA. Photo courtesy of w:ru:jenix89 (talk | contribs) and Wikipedia.org.

The biologics clinical manufacturing plant features five independent manufacturing suites to advance the pipeline of Pfizer’s potential new biotherapeutics and vaccines.

It houses seven buildings including laboratories, clinical and commercial manufacturing suites, and support areas. The multiproduct manufacturing facility is said to have a flexible design to enable more efficient manufacturing of clinical products and also for fully facilitating the use of the latest manufacturing technologies.

Mikael Dolsten – Pfizer Chief Scientific Officer and President, Worldwide Research, Development, and Medical said: “We are excited to expand our presence in Andover with a state-of-the-art facility that is designed to provide clinical manufacturing options in a cost efficient and flexible manner to help further accelerate important treatments to patients.

“We aim to increase connectivity between our research and in-house manufacturing efforts to better inform the process, ensure quality assurance, and ultimately improve patient access to potentially life-changing treatments.”

Currently, there are nearly 2,000 employees of Pfizer in Massachusetts and the new biologics clinical manufacturing facility in Andover adds 75 more jobs to support manufacturing of supplies to be used in clinical trials in oncology, rare diseases, infectious diseases, hemophilia, and rheumatoid arthritis, and other disease areas.